This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GORDON, K. Articles by HODGEN, G. D. Search for Related Content PubMed PubMed Citation Articles by GORDON, K. Articles by HODGEN, G. D.

Suppression of Ovarian Estradiol Secretion by a Single Injection of Antide in Cynomolgus Monkeys during the Early Follicular Phase: Immediate, Sustained, and Reversible Actions^*

The Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecobgy, Eastern Virginia Medical School Norfolk, Virginia 23510
Serono Laboratories, Inc. Norwell, Massachusetts 02061
Department of Pharmacology, University of Iowa College of Medicine Iowa City, Iowa 52242-1109

Address requests for reprints to: Keith Gordon, Ph.D., The Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, 855 West Brambleton Avenue, Suite B, Norfolk, Virginia 23510.

We examined the effects of the GnRH antagonist antide on ovarian estrogen secretion after a single administration in intact cycling cynomolgus monkeys (n = 5/group) during the early follicular phase. Antide treatment on menstrual cycle day 2 resulted in a dose-dependent increase in menstrual cycle lengths (mean ± SEM) to 38 ± 3, 49 ± 8, and 96 ± 15 days for 3.0, 10.0, and 30.0 mg/kg antide, respectively, in association with inhibition of folliculogenesis and suppression of estradiol concentrations to therapeutic levels. Subsequent resumption of apparently normal ovulatory menstrual cycles occurred in all 15 individuals. In addition, all four monkeys from the group treated with 30 mg/kg antide that were available for subsequent matings became pregnant and had normal babies. Thus, no irreversible consequences or adverse effects of antide on reproductive function in these primates was observed. No allergic or other adverse reactions were found locally or systemically in these primates, even at the highest dose of antide.

To the extent that this primate model is a paradigm for clinical therapeutics, a single treatment of antide (30 mg/kg) provides sustained inhibition of ovarian estradiol secretion for about 2 months, thus demonstrating the feasibility of using antide for clinical management of steroid-dependent conditions.

^* This work was partially supported by the Contraceptive Research and Development (CONRAD) Program, Eastern Virginia Medical School, under a Cooperative Agreement (DPE-2044-A-00-6063-00) with the United States Agency for International Development (A.I.D.), and Serono Laboratories, Inc. (Norwell, MA). The views expressed by the author(s) do not necessarily reflect the views of A.I.D.

Received February 26, 1991.

This article has been cited by other articles:

				P. Morales, C. Pasten, and E. Pizarro Inhibition of In Vivo and In Vitro Fertilization in Rodents by Gonadotropin-Releasing Hormone Antagonists Biol Reprod, October 1, 2002; 67(4): 1360 - 1365. [Abstract] [Full Text] [PDF]

				P. Morales, B. Kerr, C. Oliva, E. Pizarro, and M. Kong Gonadotrophin-releasing hormone antagonists inhibit sperm binding to the human zona pellucida Hum. Reprod., August 1, 1999; 14(8): 2069 - 2074. [Abstract] [Full Text] [PDF]